I think co-factor will be huge! Nice to see this stock finally turning a corner and crossing the ever important 200 day moving avg. Phase IIb results around the corner, and Ichan a huge player in the stock.

I incorrectly got into this stock looking for a momo play, but it didn't work out. I am still long and even adding more in the 1.60s. I am still bullish long term, and the stock now carries a 10% short position, although only a short ratio of 2.5. The stock was heavily pumped leading up to the FDA advisory panels unanimous vote to recommend Pfiezer's drug Maraviroc for approval, which is a new class of HIV drug that prohibits HIV from entering healthy cells via the CCR5 co-receptor. Pfiezer just recently received an approvable letter for Maraviroc, meaning the drug can't receive final approval until Pfiezer satisfies certain requirements put forth by the FDA. Monogram's Assay was used to screen for patients in clinical trials with a certain type of HIV in which the drug is effective. When this drug hits the market Monogram will more than likely be the ones providing these lab tests to screen for the HIV patients that this drug will benefit. On their last CC, it was stated by one of the clinicians that was involved in the studies on Maraviroc that Monogram is "the only game in town" for providing these necessary tests. As far as those wondering what the FDA requires to gain final approval for maraviroc, nobody knows. More than likely a labeling issue, or something minor. The FDA had no problems with the safety profile or the efficacy of Maraviroc and stated that no further clinical trials will be necessary. It could be tomorrow, or by August that they finally get that approval, but the longer the time it takes the better in my view, as it gives us longs time to load the boat. Monogram is also working on an Oncology test for breast cancer called e-tag, which could be commercially available by as early as Q1 08. This is going to be the real revenue generator for Monogram. I am a huge buyer here at these low levels.

Still waiting for this stock to breakout above that 7.00 resistance. Its a low floater, so there is the risk of volatility, but its beta is surprisingly low. Nice balance sheet with 30% growth rate. Buy on all the dips. If we get a large volume break-through above 7.00, this thing won't look back. Nice play on consumers getting more involved in taking more responsibility for their healthcare.

I believe there was a severe over-reaction to the phase III results for this company's antibiotic drug Cethromycin. The drug met its primary endpoint of showing non-inferiority as compared to Abbott Lab's Bioxin. Bioxin had a 95% success rate against treating pneumonia (best ever clinical results for Bioxin by the way), while Cethromycin had a greater than 91% success rate. The real appeal to Cethromycin is that it is a new class of antibiotic known as a ketolide antibiotic. It is supposed to be effective in antibiotic resistant pneumonia. I think a lot of retail investors have failed to understand that this was POSITIVE data, and met its primary endpoint. The endpoint wasn't to show superiority to Bioxin, only to show non-inferiority. The government is also interested in this drug as a possible Anthrax treatment. Stay tuned to the CC on July 2, and also the second phase III results this summer.

P/E ratio is pathetic for this stock... high short ratio (over 20%). I would be stacking up for the long haul as it is a key supplier to 3G wireless industry. P/E should be twice what it is, and that is being very conservative.

I think all these oil service stocks deserve higher multiples, and keep blowing out the numbers. These stocks deserve multiples in the 20s minimum.